Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record.

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial

Fahlén, Mia, Fornander, Tommy, Johansson, Hemming, Johansson, Ulla, Rutqvist, Lars-Erik, Wilking, Nils, von Schoultz, Eva · 2013 · European Journal of Cancer

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2012.07.003

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 26

  1. Hickey, 2005, Management of menopausal symptoms in patients with breast cancer: an evidence-based approach, Lancet Oncol, 6, 687, 10.1016/S1470-2045(05)70316-8 · DOI
  2. Holmberg, 2004, HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped, The Lancet, 363, 453, 10.1016/S0140-6736(04)15493-7 · DOI · Paper page
  3. von Schoultz, 2005, Menopausal hormone therapy after breast cancer: The Stockholm randomized trial, J Natl Cancer Inst, 97, 533, 10.1093/jnci/dji071 · DOI · Paper page
  4. Holmberg, 2008, Increased risk of recurrence after hormone replacement therapy in breast cancer survivors, J Natl Cancer Inst, 100, 475, 10.1093/jnci/djn058 · DOI · Paper page
  5. Clark, 2002, Quantification of the completeness of follow-up, The Lancet, 359, 1309, 10.1016/S0140-6736(02)08272-7 · DOI · Paper page
  6. Prentice, 1978, The analysis of failure times in the presence of competing risks, Biometrics, 34, 541, 10.2307/2530374 · DOI · Paper page
  7. DiSaia, 2000, Breast cancer survival and hormone replacement therapy: a cohort analysis, Am J Clin Oncol, 23, 541, 10.1097/00000421-200012000-00001 · DOI
  8. Xydakis, 2006, Hormone replacement therapy in breast cancer survivors, Ann NY Acad Sci, 1092, 349, 10.1196/annals.1365.032 · doi:10.1196/annals.1365.032
  9. Col, 2005, Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence, Breast Cancer Res, 7, R535, 10.1186/bcr1035 · DOI
  10. Batur, 2006, Menopausal hormone therapy (HT) in patients with breast cancer, Maturitas, 53, 123, 10.1016/j.maturitas.2005.03.004 · DOI
  11. Santen, 2010, Postmenopausal hormone therapy: an Endocrine Society Scientific Statement, J Clin Endocrinol Metab, 95, S1, 10.1210/jc.2009-2509 · DOI · Paper page
  12. Kenemans, 2009, Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised non-inferiority trial, Lancet Oncol, 10, 135, 10.1016/S1470-2045(08)70341-3 · DOI · Paper page
  13. Fournier, 2009, Estrogen-progestogen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risk?, J Clin Oncol, 27, 5138, 10.1200/JCO.2008.21.6432 · DOI
  14. Beral, 2011, Breast cancer risk in relation to the interval between menopause and starting hormone therapy, J Natl Cancer Inst, 103, 296, 10.1093/jnci/djq527 · DOI · Paper page
  15. Song, 2005, Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells, Apoptosis, 10, 667, 10.1007/s10495-005-1903-2 · DOI
  16. Lewis, 2005, Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation, J Natl Cancer Inst, 97, 1746, 10.1093/jnci/dji400 · DOI · Paper page
  17. Schairer, 2000, Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk, JAMA, 283, 485, 10.1001/jama.283.4.485 · DOI · Paper page
  18. Collins, 2005, Breast cancer risk with postmenopausal hormone treatment, Hum Reprod Update, 11, 545, 10.1093/humupd/dmi028 · DOI · Paper page
  19. Prentice, 2008, Conjugated equine estrogens and breast cancer risk in the Women’s Health Initiative clinical trial and observational study, Am J Epidemiol, 167, 1407, 10.1093/aje/kwn090 · DOI
  20. Conner, 2008, Breast cancer and hormonal therapy, Clin Obstet Gynecol, 51, 592, 10.1097/GRF.0b013e318180b8ed · DOI
  21. Swedish Breast Cancer Cooperative Group, 1996, Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early-stage breast cancer, J Natl Cancer Inst, 88, 1543, 10.1093/jnci/88.21.1543 · DOI · Paper page
  22. 1998, Tamoxifen for early breast cancer: an overview of the randomized trials, Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4 · DOI · Paper page
  23. Osborne, 2009, The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer, Breast Cancer Res Treat, 116, 521, 10.1007/s10549-008-0284-y · DOI
  24. Sestak, 2006, Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms, J Clin Oncol, 24, 3991, 10.1200/JCO.2005.04.3745 · DOI
  25. Fahlén, 2011, Health-related quality of life during hormone therapy after breast cancer: a randomized trial, Climacteric, 14, 164, 10.3109/13697131003660593 · DOI
  26. Marsden, 2000, Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?, Fertil Steril, 73, 292, 10.1016/S0015-0282(99)00510-5 · DOI

Cited by

Metadata

Authors
Fahlén, M., Fornander, T., Johansson, H., Johansson, U., Rutqvist, L.-E., Wilking, N., & von Schoultz, E.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2013-01
Volume
49
Issue
1
Pages
52-59
ISSN
0959-8049 (ISSN-L)
OpenAlex
W2121476566
Cited by
158
References
0
FWCI
5.06
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Stockholm Cancer Society
  • King Gustav V Jubilee Fund
  • Stockholm County Council
  • Karolinska Institutet

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.